Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 2/20 | 0.61 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.61 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.61 |
| ▸ | KDM1A | O60341 | 7/20 | 0.46 |
| ▸ | NOS3 | P29474 | 2/20 | 0.45 |
| ▸ | NOS1 | P29475 | 2/20 | 0.45 |
| ▸ | NOS2 | P35228 | 2/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.45 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29478759 | 1.00 | PRSS1 (0.61) | PRSS1PRSS2PRSS3KDM1ANOS3 | |
| SCHEMBL320096 | 1.00 | PRSS1 (0.61) | PRSS1PRSS2PRSS3KDM1ANOS3 | |
| SCHEMBL9968925 | 1.00 | PRSS1 (0.61) | PRSS1PRSS2PRSS3KDM1ANOS3 | |
| SCHEMBL2786857 | 0.85 | CYP4F2 (0.50) | PRSS1PRSS2PRSS3KDM1AGRIN2B | |
| SCHEMBL9968926 | 0.85 | CYP4F2 (0.50) | PRSS1PRSS2PRSS3KDM1AGRIN2B | |
| SCHEMBL320211 | 0.85 | CYP4F2 (0.50) | PRSS1PRSS2PRSS3KDM1AGRIN2B | |
| SCHEMBL405393 | 0.79 | AKR1B1 (0.47) | KDM1AL3MBTL1 | |
| SCHEMBL405392 | 0.79 | AKR1B1 (0.47) | KDM1AL3MBTL1 | |
| SCHEMBL409609 | 0.79 | TSHR (0.44) | PRSS1PRSS2PRSS3KDM1AGRIN2B | |
| SCHEMBL2772408 | 0.79 | KDM1A (0.46) | PRSS1PRSS2PRSS3KDM1AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-08-18 | — | — | US | disclosed |
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-08-18 | — | — | US | disclosed |
| EP-3962481-A1 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| WO-2020227101-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| EP-2250165-B1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2018-07-25 | — | — | EP | disclosed |
| EP-2250165-B1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO SA (CH) | 2018-07-25 | — | — | EP | disclosed |
| EP-2414341-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-09-13 | — | — | EP | disclosed |
| EP-2414341-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-09-13 | — | — | EP | disclosed |
| EP-2414342-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-05-31 | — | — | EP | disclosed |
| EP-2414342-B1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2017-05-31 | — | — | EP | disclosed |
| US-7671043-B2 | Cycloalkylamino acid derivatives | PFIZER INC (US) | 2010-03-02 | — | — | US | disclosed |
| WO-2009080663-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO S.A. (CH) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080663-A1 | TRIAZOLE OXADIAZOLES DERIVATIVES | MERCK SERONO S.A. (CH) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009043889-A2 | OXADIAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2009-04-09 | — | — | WO | disclosed |
| EP-2021338-A1 | CYCLOALKYLAMINO ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | Pfizer Products Inc. (US) | 2009-02-11 | — | — | EP | disclosed |
| WO-2007132307-A1 | CYCLOALKYLAMINO ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER PRODUCTS INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007132307-A1 | CYCLOALKYLAMINO ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER PRODUCTS INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070270438-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | PFIZER INC | 2007-11-22 | — | — | US | disclosed |
| US-20070270438-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | PFIZER INC | 2007-11-22 | — | — | US | disclosed |
| US-20070270438-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | PFIZER INC | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270438-A1 | CYCLOALKYLAMINO ACID DERIVATIVES | CCND1, CCND2, CCND3 | PRSS1 1150/4885PRSS2 2271/4885PRSS3 1665/4885 |
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | PRSS1 1601/4885PRSS2 2236/4885PRSS3 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.